Research advances in systemic therapy for advanced hepatocellular carcinoma
10.3969/j.issn.1001-5256.2021.12.044
- VernacularTitle:晚期肝细胞癌系统治疗的研究进展
- Author:
Shisi LI
1
;
Zhitang GUO
1
;
Zhangbin CHEN
1
;
Yishan TENG
1
Author Information
1. The Third Ward of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
- Publication Type:Reviews
- Keywords:
Carcinoma, Hepatocellular;
Drug Therapy;
Immunotherapy
- From:
Journal of Clinical Hepatology
2021;37(12):2943-2946
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is a common malignant tumor with poor prognosis, and surgical resection is the preferred method for the treatment of HCC, but it has a limited therapeutic effect on advanced HCC, while systemic treatment plays an important role in the treatment of advanced unresectable HCC. This article summarizes the advances in systemic therapy for unresectable liver cancer in China and globally in recent years, including a variety of tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib, and cabozantinib) and immune checkpoint inhibitors (atezolizumab, pembrolizumab, and nivolumab). The analysis shows that for patients with unresectable HCC, systemic therapy can prolong the survival time of patients to a certain extent, and combined treatment regimen has become a new research hotspot. Individualized systemic treatment strategies will be further explored in the future.
